MA40457A - Combinaison de médicaments pour traiter le myélome multiple - Google Patents
Combinaison de médicaments pour traiter le myélome multipleInfo
- Publication number
- MA40457A MA40457A MA040457A MA40457A MA40457A MA 40457 A MA40457 A MA 40457A MA 040457 A MA040457 A MA 040457A MA 40457 A MA40457 A MA 40457A MA 40457 A MA40457 A MA 40457A
- Authority
- MA
- Morocco
- Prior art keywords
- multiple myeloma
- drug combinations
- treat multiple
- treat
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne une combinaison d'un inhibiteur de c-met et d'un inhibiteur du protéasome pour traiter le cancer, notamment le myélome multiple.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462033386P | 2014-08-05 | 2014-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40457A true MA40457A (fr) | 2017-06-14 |
Family
ID=53836256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040457A MA40457A (fr) | 2014-08-05 | 2015-08-05 | Combinaison de médicaments pour traiter le myélome multiple |
Country Status (13)
Country | Link |
---|---|
US (1) | US11065240B2 (fr) |
EP (1) | EP3177311A1 (fr) |
JP (2) | JP6892381B2 (fr) |
KR (1) | KR102634247B1 (fr) |
CN (1) | CN106573042A (fr) |
AU (1) | AU2015301097B2 (fr) |
BR (1) | BR112017002318A2 (fr) |
CA (1) | CA2957466C (fr) |
EA (1) | EA034992B1 (fr) |
MA (1) | MA40457A (fr) |
MX (1) | MX2017001490A (fr) |
UA (1) | UA121482C2 (fr) |
WO (1) | WO2016022697A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
UA123534C2 (uk) | 2014-02-14 | 2021-04-21 | Екселіксис, Інк. | Кристалічні тверді форми n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-флуорофеніл)циклопропан-1,1-дикарбоксаміду, способи отримання і способи застосування |
MA39735A (fr) | 2014-03-17 | 2017-01-25 | Exelixis Inc | Dosage de préparations de cabozantinib |
US11124481B2 (en) | 2014-07-31 | 2021-09-21 | Exelixis, Inc. | Method of preparing fluorine-18 labeled Cabozantinib and its analogs |
CA2957466C (fr) | 2014-08-05 | 2023-10-17 | Exelixis, Inc. | Combinaison de medicaments pour traiter le myelome multiple |
EP3442531A1 (fr) | 2016-04-15 | 2019-02-20 | Exelixis, Inc. | Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
WO2019053611A1 (fr) * | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Polythérapie pour le traitement du cancer |
CN117603138A (zh) | 2018-01-26 | 2024-02-27 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
WO2023222946A1 (fr) | 2022-05-18 | 2023-11-23 | Fermion Oy | Procédé de préparation de cabozantinib |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6402215B1 (en) * | 1996-05-21 | 2002-06-11 | American Moto Products, Inc. | Vehicle cargo bed extender |
ES2925655T3 (es) | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
CA2572331A1 (fr) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | Modulateurs de c-met et leur methode d'utilisation |
CA2603748A1 (fr) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | Modulateurs c-met modulators et procedes d'utilisation |
PL2101759T3 (pl) | 2006-12-14 | 2019-05-31 | Exelixis Inc | Sposoby stosowania inhibitorów MEK |
UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
MX2011005038A (es) | 2008-11-13 | 2011-06-16 | Exelisis Inc | Metodo de preparacion de derivados de quinolina. |
JP2012511017A (ja) | 2008-12-04 | 2012-05-17 | エグゼリクシス, インコーポレイテッド | キノリン誘導体の調製方法 |
TWI447108B (zh) | 2009-01-16 | 2014-08-01 | Exelixis Inc | N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型 |
NZ597695A (en) | 2009-07-17 | 2014-05-30 | Exelixis Inc | Crystalline forms of n-[3-fluoro-4-({ 6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl} oxy)phenyl]-n’-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
CN102812027B (zh) * | 2010-02-03 | 2015-01-07 | 因西特公司 | 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪 |
MX2012010506A (es) | 2010-03-12 | 2012-10-15 | Exelixis Inc | Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida. |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
US20140186407A9 (en) | 2010-07-16 | 2014-07-03 | Exelixis Inc. | C-Met Modulator Pharmaceutical Compositions |
CN103221035A (zh) | 2010-07-16 | 2013-07-24 | 埃克塞里艾克西斯公司 | C-met调节剂药物组合物 |
US20140057908A1 (en) | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
JP2013540759A (ja) | 2010-09-27 | 2013-11-07 | エクセリクシス, インク. | 去勢抵抗性前立腺癌および造骨性転移の治療のためのmetおよびvegfの二元阻害薬 |
EP2621481B2 (fr) | 2010-09-27 | 2022-10-19 | Exelixis, Inc. | Inhibiteurs de met et vegf à double effet pour le traitement du cancer de la prostate résistant à la castration et des métastases osseuses ostéoblastiques |
WO2012064967A2 (fr) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Le récepteur activateur du ligand nf-kb, issu de cellules cancéreuses, entraîne des métastases des os et des tissus mous |
US20130252956A1 (en) | 2010-11-22 | 2013-09-26 | Howard Kallender | Methods of treating cancer |
KR20190049907A (ko) | 2011-02-10 | 2019-05-09 | 엑셀리시스, 인코포레이티드 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
EA029506B1 (ru) | 2011-05-02 | 2018-04-30 | Экселиксис, Инк. | Способ лечения рака и раковой боли в костях |
TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
EA201490676A1 (ru) | 2011-09-22 | 2015-02-27 | Экселиксис, Инк. | Способ лечения остеопороза |
TWI619694B (zh) | 2011-10-20 | 2018-04-01 | 艾克塞里克斯公司 | 用於製備喹啉衍生物之方法 |
TW201818937A (zh) | 2011-11-08 | 2018-06-01 | 美商艾克塞里克斯公司 | 治療癌症之方法 |
EP2812354A4 (fr) * | 2012-02-06 | 2016-03-09 | Univ California | Régulation de l'angiogenèse par emp2 dans les cellules cancéreuses par le biais de l'induction de vegf |
CN103304552B (zh) * | 2012-03-09 | 2016-12-28 | 广东东阳光药业有限公司 | 取代的吡啶化合物及其使用方法和用途 |
EP2844254A1 (fr) | 2012-05-02 | 2015-03-11 | Exelixis, Inc. | Double modulateur met-vegf pour traiter des métastases osseuses ostéolytiques |
US20150238477A1 (en) | 2012-09-07 | 2015-08-27 | Exelixis, Inc. | Method of Treating Lung Adenocarcinoma |
US20140221372A1 (en) | 2013-02-06 | 2014-08-07 | GlaxoSmithKline Intellectual Property (NO 2.) Limited | Method of administration and treatment |
CN105121412B (zh) | 2013-03-15 | 2019-07-12 | 埃克塞里艾克西斯公司 | N-(4-{[6,7-双(甲基氧基)喹啉-4-基]氧基}苯基)-n′-(4-氟苯基)环丙烷-1,1-二甲酰胺的代谢物 |
EP2981263B1 (fr) | 2013-04-04 | 2022-06-29 | Exelixis, Inc. | Formulation de dosage du cabozantinib et utilisation dans le traitement du cancer |
JP2016515628A (ja) | 2013-04-04 | 2016-05-30 | エグゼリクシス, インコーポレイテッド | 癌を治療するための複合薬 |
UA123534C2 (uk) | 2014-02-14 | 2021-04-21 | Екселіксис, Інк. | Кристалічні тверді форми n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-флуорофеніл)циклопропан-1,1-дикарбоксаміду, способи отримання і способи застосування |
MA39735A (fr) | 2014-03-17 | 2017-01-25 | Exelixis Inc | Dosage de préparations de cabozantinib |
EP3906921A1 (fr) | 2014-04-25 | 2021-11-10 | Exelixis, Inc. | Procédé de traitement de l'adénocarcinome pulmonaire |
US11124481B2 (en) | 2014-07-31 | 2021-09-21 | Exelixis, Inc. | Method of preparing fluorine-18 labeled Cabozantinib and its analogs |
CA2957466C (fr) | 2014-08-05 | 2023-10-17 | Exelixis, Inc. | Combinaison de medicaments pour traiter le myelome multiple |
US20170224670A1 (en) | 2014-10-14 | 2017-08-10 | Exelixis, Inc. | Drug Combination to Treat Melanoma |
-
2015
- 2015-08-05 CA CA2957466A patent/CA2957466C/fr active Active
- 2015-08-05 JP JP2017506390A patent/JP6892381B2/ja active Active
- 2015-08-05 UA UAA201702039A patent/UA121482C2/uk unknown
- 2015-08-05 US US15/501,582 patent/US11065240B2/en active Active
- 2015-08-05 CN CN201580042010.4A patent/CN106573042A/zh active Pending
- 2015-08-05 MA MA040457A patent/MA40457A/fr unknown
- 2015-08-05 KR KR1020177006288A patent/KR102634247B1/ko active IP Right Grant
- 2015-08-05 EP EP15750223.8A patent/EP3177311A1/fr active Pending
- 2015-08-05 EA EA201790312A patent/EA034992B1/ru not_active IP Right Cessation
- 2015-08-05 AU AU2015301097A patent/AU2015301097B2/en active Active
- 2015-08-05 BR BR112017002318-0A patent/BR112017002318A2/pt active Search and Examination
- 2015-08-05 MX MX2017001490A patent/MX2017001490A/es unknown
- 2015-08-05 WO PCT/US2015/043825 patent/WO2016022697A1/fr active Application Filing
-
2019
- 2019-10-10 JP JP2019186703A patent/JP2020002179A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020002179A (ja) | 2020-01-09 |
CA2957466C (fr) | 2023-10-17 |
AU2015301097B2 (en) | 2021-03-04 |
WO2016022697A1 (fr) | 2016-02-11 |
JP2017526662A (ja) | 2017-09-14 |
EA034992B1 (ru) | 2020-04-15 |
KR102634247B1 (ko) | 2024-02-05 |
US20170224672A1 (en) | 2017-08-10 |
CA2957466A1 (fr) | 2016-02-11 |
CN106573042A (zh) | 2017-04-19 |
EA201790312A1 (ru) | 2017-06-30 |
KR20170031786A (ko) | 2017-03-21 |
EP3177311A1 (fr) | 2017-06-14 |
UA121482C2 (uk) | 2020-06-10 |
AU2015301097A1 (en) | 2017-03-02 |
BR112017002318A2 (pt) | 2018-07-17 |
MX2017001490A (es) | 2017-05-11 |
US11065240B2 (en) | 2021-07-20 |
JP6892381B2 (ja) | 2021-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501763A1 (en) | Multispecific antibodies | |
MY184870A (en) | Immunomodulators | |
HUE053191T2 (hu) | 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére | |
PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
MX2017000363A (es) | Inhibicion de la via de notch. | |
MA40457A (fr) | Combinaison de médicaments pour traiter le myélome multiple | |
AU2019268074A1 (en) | Methods for treating hepcidin-mediated disorders | |
PL3122358T3 (pl) | Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu | |
ECSP17015977A (es) | Terapia de combinacion | |
MX2016011160A (es) | Tratamiento de afecciones asociadas con la hiperinsulinemia. | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
IN2015DE00625A (fr) | ||
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
MX2017012553A (es) | Compuestos espirociclicos. | |
MX2020007742A (es) | Procesos para preparar fluorocetolidos. | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
PH12017500071A1 (en) | Therapeutic agent for keratoconjunctive disorder | |
UA104671U (uk) | Застосування яктону як нейропротектора | |
AU366435S (en) | Dry pipe | |
IN2014MU03184A (fr) | ||
UA99992U (ru) | 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния | |
UA103911U (ru) | Средство с вазодилатирующей активностью | |
TN2014000468A1 (fr) | اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها |